Regenxbio Net Tangible Assets vs Total Assets Analysis

RGNX Stock  USD 9.18  0.45  4.67%   
Regenxbio financial indicator trend analysis is much more than just breaking down Regenxbio prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regenxbio is a good investment. Please check the relationship between Regenxbio Net Tangible Assets and its Total Assets accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regenxbio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.

Net Tangible Assets vs Total Assets

Net Tangible Assets vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regenxbio Net Tangible Assets account and Total Assets. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Regenxbio's Net Tangible Assets and Total Assets is 0.95. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Total Assets in the same time period over historical financial statements of Regenxbio, assuming nothing else is changed. The correlation between historical values of Regenxbio's Net Tangible Assets and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Regenxbio are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Net Tangible Assets i.e., Regenxbio's Net Tangible Assets and Total Assets go up and down completely randomly.

Correlation Coefficient

0.95
Relationship DirectionPositive 
Relationship StrengthVery Strong

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Total Assets

Total assets refers to the total amount of Regenxbio assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Regenxbio books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from Regenxbio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regenxbio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regenxbio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.Sales General And Administrative To Revenue is likely to rise to 1.49 in 2024, whereas Selling General Administrative is likely to drop slightly above 47.8 M in 2024.
 2021 2022 2023 2024 (projected)
Gross Profit418.5M58.2M53.0M91.4M
Total Revenue470.3M112.7M90.2M111.6M

Regenxbio fundamental ratios Correlations

0.860.840.830.960.75-0.58-0.540.710.790.950.960.84-0.630.890.750.920.890.960.53-0.630.950.670.610.680.89
0.860.950.940.70.45-0.33-0.750.870.640.830.790.78-0.470.790.880.870.980.810.76-0.470.780.340.430.590.91
0.840.951.00.720.46-0.22-0.830.920.550.830.770.74-0.480.80.980.860.90.790.84-0.480.80.390.460.60.98
0.830.941.00.710.45-0.18-0.850.940.510.820.760.73-0.490.80.980.860.890.780.86-0.490.80.390.420.630.97
0.960.70.720.710.82-0.55-0.430.60.720.920.930.76-0.670.860.650.870.730.930.42-0.670.960.760.60.690.81
0.750.450.460.450.82-0.5-0.170.340.570.740.70.69-0.590.690.360.670.50.70.14-0.590.740.470.590.50.56
-0.58-0.33-0.22-0.18-0.55-0.5-0.20.07-0.93-0.48-0.63-0.530.29-0.35-0.07-0.32-0.51-0.610.260.29-0.42-0.36-0.620.02-0.29
-0.54-0.75-0.83-0.85-0.43-0.17-0.2-0.93-0.14-0.46-0.54-0.550.48-0.68-0.88-0.73-0.63-0.56-0.970.48-0.6-0.240.04-0.66-0.81
0.710.870.920.940.60.340.07-0.930.280.670.660.64-0.490.760.910.830.770.680.95-0.490.70.360.120.740.88
0.790.640.550.510.720.57-0.93-0.140.280.70.810.73-0.410.580.410.580.780.810.09-0.410.640.440.670.20.59
0.950.830.830.820.920.74-0.48-0.460.670.70.830.7-0.530.80.760.850.840.840.5-0.530.910.570.730.570.86
0.960.790.770.760.930.7-0.63-0.540.660.810.830.88-0.670.90.660.90.841.00.49-0.670.920.720.450.710.84
0.840.780.740.730.760.69-0.53-0.550.640.730.70.88-0.50.80.630.820.830.90.49-0.50.780.510.340.650.76
-0.63-0.47-0.48-0.49-0.67-0.590.290.48-0.49-0.41-0.53-0.67-0.5-0.66-0.45-0.65-0.44-0.67-0.481.0-0.69-0.46-0.17-0.54-0.57
0.890.790.80.80.860.69-0.35-0.680.760.580.80.90.8-0.660.740.980.780.910.62-0.660.910.670.370.830.88
0.750.880.980.980.650.36-0.07-0.880.910.410.760.660.63-0.450.740.80.80.690.88-0.450.760.340.410.580.95
0.920.870.860.860.870.67-0.32-0.730.830.580.850.90.82-0.650.980.80.850.910.69-0.650.940.620.390.840.91
0.890.980.90.890.730.5-0.51-0.630.770.780.840.840.83-0.440.780.80.850.860.62-0.440.770.390.50.530.87
0.960.810.790.780.930.7-0.61-0.560.680.810.841.00.9-0.670.910.690.910.860.52-0.670.920.710.450.720.85
0.530.760.840.860.420.140.26-0.970.950.090.50.490.49-0.480.620.880.690.620.52-0.480.570.24-0.040.650.79
-0.63-0.47-0.48-0.49-0.67-0.590.290.48-0.49-0.41-0.53-0.67-0.51.0-0.66-0.45-0.65-0.44-0.67-0.48-0.69-0.46-0.17-0.54-0.57
0.950.780.80.80.960.74-0.42-0.60.70.640.910.920.78-0.690.910.760.940.770.920.57-0.690.710.540.760.88
0.670.340.390.390.760.47-0.36-0.240.360.440.570.720.51-0.460.670.340.620.390.710.24-0.460.710.220.740.49
0.610.430.460.420.60.59-0.620.040.120.670.730.450.34-0.170.370.410.390.50.45-0.04-0.170.540.22-0.040.5
0.680.590.60.630.690.50.02-0.660.740.20.570.710.65-0.540.830.580.840.530.720.65-0.540.760.74-0.040.66
0.890.910.980.970.810.56-0.29-0.810.880.590.860.840.76-0.570.880.950.910.870.850.79-0.570.880.490.50.66
Click cells to compare fundamentals

Regenxbio Account Relationship Matchups

Regenxbio fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets497.9M708.2M1.1B833.3M574.0M487.0M
Short Long Term Debt Total11.3M72.7M86.7M94.8M89.3M50.0M
Other Current Liab21.5M62.2M100.9M89.4M93.2M97.9M
Total Current Liabilities33.7M81.4M130.5M130.4M130.3M136.8M
Total Stockholder Equity450.2M377.8M764.3M516.2M311.7M348.3M
Net Debt(58.2M)(265.8M)(258.5M)(2.2M)54.8M57.5M
Retained Earnings(177.8M)(289.1M)(161.2M)(441.6M)(705.0M)(669.8M)
Accounts Payable6.4M10.6M11.4M27.2M22.8M23.9M
Cash69.5M338.4M345.2M97.0M34.5M32.8M
Non Current Assets Total152.9M177.0M595.1M417.3M239.0M200.1M
Cash And Short Term Investments296.2M475.7M457.4M364.6M275.3M255.6M
Net Receivables38.1M43.0M32.4M28.1M26.3M18.3M
Common Stock Shares Outstanding36.7M37.3M43.9M43.2M43.7M33.3M
Liabilities And Stockholders Equity497.9M708.2M1.1B833.3M574.0M487.0M
Other Current Assets4.2M12.5M28.9M23.3M33.4M35.0M
Other Stockholder Equity627.8M667.2M928.1M973.1M1.0B551.6M
Total Liab47.7M330.4M349.6M317.1M262.2M138.7M
Total Current Assets345.0M531.2M518.8M416.0M335.0M286.9M
Accumulated Other Comprehensive Income205K(360K)(2.6M)(15.4M)(4.4M)(4.2M)
Net Tangible Assets450.2M377.8M764.3M516.2M593.6M386.3M
Non Currrent Assets Other10.0M9.9M10.7M9.9M4.8M8.1M
Other Assets10.0M8.8M1.1B9.9M11.4M10.8M
Short Term Investments226.7M137.3M112.2M267.7M240.7M168.1M
Inventory6.5M10.5M18.8M13.9M16.0M16.8M
Long Term Investments103.8M50.1M394.2M200.6M38.9M36.9M
Property Plant Equipment39.1M56.5M192.5M206.8M237.8M249.7M
Other Liab5.2M178.8M134.2M97.8M112.5M58.5M
Property Plant And Equipment Net39.1M120.3M192.5M206.8M192.6M98.2M
Retained Earnings Total Equity(83.0M)(177.8M)(289.1M)(161.2M)(145.1M)(152.4M)
Non Current Liabilities Total14.0M249.0M219.1M186.6M132.0M99.8M
Capital Surpluse592.6M627.8M667.2M928.1M1.1B586.6M
Property Plant And Equipment Gross39.1M120.3M192.5M206.8M249.8M262.3M
Net Invested Capital450.2M377.8M764.3M516.2M311.7M489.0M
Net Working Capital311.4M449.8M388.4M285.5M204.7M331.4M
Capital Lease Obligations11.3M72.7M86.7M94.8M89.3M66.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Regenxbio Stock Analysis

When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.